Product Description
For Moderate to Severe Chronic Pain Due to Osteoarthritis of the Knee (Sourced from: https://clinicaltrials.gov/ct2/show/NCT02847702)
Mechanisms of Action: TRKA Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Purdue Pharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Osteoarthritis, Knee
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT02847702 |
TKA2001 | P2 |
Terminated |
Osteoarthritis, Knee |
2016-11-22 |
2019-03-20 |
Treatments |
Recent News Events
Date |
Type |
Title |
|---|